|
US5981568A
(en)
*
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
ES2098188B1
(es)
*
|
1995-05-11 |
1997-12-16 |
Univ Santiago Compostela |
Desarrollo de nanoparticulas a base de polimeros hidrofilicos.
|
|
US20010009904A1
(en)
*
|
1997-12-30 |
2001-07-26 |
Jon A. Wolff |
Process of delivering a polynucleotide to a cell via the vascular system
|
|
DE69712110T2
(de)
*
|
1996-07-10 |
2002-12-12 |
West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham |
Zusammensetzungen zur einführung von genen in epithelzellen
|
|
ES2114502B1
(es)
*
|
1996-07-29 |
1999-07-01 |
Univ Santiago Compostela |
Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
|
|
US6649192B2
(en)
*
|
1996-07-29 |
2003-11-18 |
Universidade De Santiago De Compostela |
Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
|
|
DE19746362A1
(de)
*
|
1996-10-23 |
1998-04-30 |
Sueddeutsche Kalkstickstoff |
Verfahren zur Herstellung von biologisch aktiven Polymernanopartikel-Nucleinsäure-Konjugaten
|
|
US6387700B1
(en)
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
|
ES2195317T3
(es)
|
1997-01-30 |
2003-12-01 |
Chiron Corp |
Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
|
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
|
EP1275380A1
(de)
*
|
1997-01-30 |
2003-01-15 |
Chiron Corporation |
Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
|
|
EP0860167A1
(de)
*
|
1997-01-30 |
1998-08-26 |
Robert Gurny |
DNA und RNA Wirkstoffderivate in Nanopartikeln
|
|
WO2000006123A1
(en)
*
|
1998-07-29 |
2000-02-10 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
|
JP2001521503A
(ja)
*
|
1997-03-31 |
2001-11-06 |
ネオルックス コーポレイション |
血管平滑筋細胞の治療的阻害物質
|
|
WO1998047492A1
(en)
*
|
1997-04-18 |
1998-10-29 |
Vertex Pharmaceuticals Incorporated |
Nanosized aspartyl protease inhibitors
|
|
US5885609A
(en)
*
|
1997-05-23 |
1999-03-23 |
Northeastern University |
Biocompatible articles and method for making same
|
|
EP1037670B1
(de)
*
|
1997-12-12 |
2003-11-05 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Mittel zur gentherapie von tumorerkrankungen, neurodegenerativen, herzkreislauf- und autoimmunerkrankungen
|
|
US6254890B1
(en)
|
1997-12-12 |
2001-07-03 |
Massachusetts Institute Of Technology |
Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
|
|
US6395253B2
(en)
*
|
1998-04-23 |
2002-05-28 |
The Regents Of The University Of Michigan |
Microspheres containing condensed polyanionic bioactive agents and methods for their production
|
|
KR19990085365A
(ko)
*
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
WO2000000180A1
(de)
*
|
1998-06-29 |
2000-01-06 |
White Spot Ag |
Verwendung von wachstumsfaktoren zur arzneimittelherstellung
|
|
US7008645B2
(en)
*
|
1998-07-14 |
2006-03-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Method of inhibiting restenosis using bisphosphonates
|
|
IL125336A0
(en)
*
|
1998-07-14 |
1999-03-12 |
Yissum Res Dev Co |
Compositions for inhibition and treatment of restinosis
|
|
US7087236B1
(en)
|
1998-09-01 |
2006-08-08 |
Merrion Research I Limited |
Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
|
|
DE69930753D1
(de)
*
|
1998-09-01 |
2006-05-18 |
Elan Corp Plc Dublin |
Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
|
|
CA2341352C
(en)
*
|
1998-09-01 |
2013-01-08 |
Elan Corporation Plc |
Oral vaccine compositions
|
|
US6689121B1
(en)
*
|
1998-09-24 |
2004-02-10 |
C. R. Bard, Inc. |
Systems and methods for treating ischemia
|
|
US6251079B1
(en)
|
1998-09-30 |
2001-06-26 |
C. R. Bard, Inc. |
Transthoracic drug delivery device
|
|
US6458092B1
(en)
|
1998-09-30 |
2002-10-01 |
C. R. Bard, Inc. |
Vascular inducing implants
|
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
|
US7521068B2
(en)
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
|
AU3471400A
(en)
*
|
1999-01-19 |
2000-08-07 |
Children's Hospital Of Philadelphia, The |
Compositions and methods for controlled delivery of virus vectors
|
|
JP2003503308A
(ja)
*
|
1999-02-02 |
2003-01-28 |
セーフサイエンス インコーポレイテッド |
遺伝子治療の送達系及び方法
|
|
EP1471034A3
(de)
*
|
1999-02-03 |
2005-03-02 |
Biosante Pharmaceuticals, Inc. |
Therapeutische kalzium-phosphat Partikel und Methoden zu deren Herstellung und Verwendung
|
|
US6355271B1
(en)
|
1999-02-03 |
2002-03-12 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
|
JP5124066B2
(ja)
*
|
1999-03-24 |
2013-01-23 |
イギリス国 |
ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
|
|
US6620170B1
(en)
|
1999-04-26 |
2003-09-16 |
C. R. Bard, Inc. |
Devices and methods for treating ischemia by creating a fibrin plug
|
|
US6986784B1
(en)
|
1999-05-14 |
2006-01-17 |
C. R. Bard, Inc. |
Implant anchor systems
|
|
US6719805B1
(en)
|
1999-06-09 |
2004-04-13 |
C. R. Bard, Inc. |
Devices and methods for treating tissue
|
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
|
US6277082B1
(en)
|
1999-07-22 |
2001-08-21 |
C. R. Bard, Inc. |
Ischemia detection system
|
|
US6629987B1
(en)
|
1999-07-30 |
2003-10-07 |
C. R. Bard, Inc. |
Catheter positioning systems
|
|
US6855160B1
(en)
|
1999-08-04 |
2005-02-15 |
C. R. Bard, Inc. |
Implant and agent delivery device
|
|
DE19961939A1
(de)
*
|
1999-12-22 |
2001-06-28 |
Cognis Deutschland Gmbh |
Verwendung von nanoskaligen kationischen Verbindungen
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7232421B1
(en)
|
2000-05-12 |
2007-06-19 |
C. R. Bard, Inc. |
Agent delivery systems
|
|
US7527807B2
(en)
*
|
2000-06-21 |
2009-05-05 |
Cubist Pharmaceuticals, Inc. |
Compositions and methods for increasing the oral absorption of antimicrobials
|
|
US7204847B1
(en)
|
2000-07-28 |
2007-04-17 |
C. R. Bard, Inc. |
Implant anchor systems
|
|
US7829100B2
(en)
|
2000-09-12 |
2010-11-09 |
Teagarden Dirk L |
Pharmaceutical composition having modified carrier
|
|
AUPR011700A0
(en)
|
2000-09-14 |
2000-10-05 |
Austin Research Institute, The |
Composition comprising immunogenic virus sized particles (VSP)
|
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
|
WO2002026212A2
(en)
|
2000-09-28 |
2002-04-04 |
Chiron Corporation |
Microparticle compositions and methods for the manufacture thereof
|
|
EP1348034B1
(de)
*
|
2000-11-15 |
2016-07-20 |
Minerva Biotechnologies Corporation |
Oligonukleotididentifikatoren
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
EP1355919B1
(de)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
|
US6977085B2
(en)
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
|
US6607784B2
(en)
|
2000-12-22 |
2003-08-19 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US6884436B2
(en)
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
|
US6951656B2
(en)
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US7193084B2
(en)
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
|
WO2002094321A1
(en)
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
Compositions for promoting healing of bone fracture
|
|
KR20040007583A
(ko)
|
2001-05-23 |
2004-01-24 |
다나베 세이야꾸 가부시키가이샤 |
연골 질환의 재생치료용 조성물
|
|
MXPA04002446A
(es)
*
|
2001-09-26 |
2004-07-23 |
Baxter Int |
Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
|
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
|
US7112340B2
(en)
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
|
FR2836381B1
(fr)
*
|
2002-02-22 |
2004-09-10 |
Oreal |
Nanocapsules a base de polyester polyol, et compositions cosmetiques ou dermatologiques les contenant
|
|
DE10209860A1
(de)
*
|
2002-03-06 |
2003-09-25 |
Hemofarm Konzern A D |
Hydrophobe Nanotropfen mit gebundenen Hämoglobinmolekülen in hydrophiler Phase enthaltene Emulsion als Blutersatzstoff
|
|
JP4679822B2
(ja)
*
|
2002-03-13 |
2011-05-11 |
ノバルティス アーゲー |
医薬微粒子
|
|
JP2003342196A
(ja)
*
|
2002-05-31 |
2003-12-03 |
Mukku:Kk |
静脈注射用組成物、その製造法およびその製剤
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
EP2283864A1
(de)
*
|
2002-07-16 |
2011-02-16 |
Elan Pharma International Ltd. |
Flüssige Zusammensetzung enthaltend stabilisierte Wirkstoff-Nanopartikeln
|
|
FR2842737B1
(fr)
*
|
2002-07-25 |
2006-01-27 |
Centre Nat Rech Scient |
Particules revetues en surface de hyaluronane ou d'un de ses derives et leur utilisation a titre de vecteurs biologiques pour des matieres actives
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
DE60305113T2
(de)
|
2002-09-09 |
2006-12-07 |
Trigen Ltd. |
Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
|
|
US7659061B2
(en)
|
2002-11-19 |
2010-02-09 |
Pharmacia & Upjohn Company |
Pharmaceutical compositions having a modified vehicle
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
AU2004204817C1
(en)
|
2003-01-13 |
2011-01-20 |
Macrogenics, Inc. |
Soluble FcyR fusion proteins and methods of use thereof
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
CA2518223A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Ltt Bio-Pharma Co., Ltd. |
Intravenous nanoparticles for targeting drug delivery and sustained drug release
|
|
KR101224235B1
(ko)
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
재조합 ｉｌ９ 항체 및 그의 용도
|
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
|
US10517883B2
(en)
|
2003-06-27 |
2019-12-31 |
Zuli Holdings Ltd. |
Method of treating acute myocardial infarction
|
|
ES2232287B1
(es)
*
|
2003-07-04 |
2006-11-01 |
Advanced In Vitro Cell Technologies, S.L. |
Nanoparticulas de derivados polioxietilenados.
|
|
US7326571B2
(en)
|
2003-07-17 |
2008-02-05 |
Boston Scientific Scimed, Inc. |
Decellularized bone marrow extracellular matrix
|
|
EP1660186B1
(de)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanisierung von antikörpern
|
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
|
WO2005101466A2
(en)
|
2003-12-19 |
2005-10-27 |
The University Of North Carolina At Chapel Hill |
Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
|
|
US9040090B2
(en)
|
2003-12-19 |
2015-05-26 |
The University Of North Carolina At Chapel Hill |
Isolated and fixed micro and nano structures and methods thereof
|
|
CN1921880A
(zh)
*
|
2004-02-26 |
2007-02-28 |
独立行政法人科学技术振兴机构 |
蛋白质类药物的注射用缓释微粒制剂及其制造方法
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
WO2006080951A2
(en)
*
|
2004-07-01 |
2006-08-03 |
Yale University |
Targeted and high density drug loaded polymeric materials
|
|
US9006181B2
(en)
|
2004-07-21 |
2015-04-14 |
The Administrators Of The Tulane Educational Fund |
Treatment of renal dysfunction and multiple myeloma using PACAP compounds
|
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
CA2586035A1
(en)
|
2004-11-01 |
2006-05-11 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
|
|
AU2005334819B2
(en)
|
2004-11-15 |
2011-11-24 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
|
|
CA2600085A1
(en)
*
|
2005-03-09 |
2006-09-14 |
Toray Industries, Inc. |
Microparticle and pharmaceutical preparation
|
|
EP1869192B1
(de)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Rahmenmischung von antikörpern
|
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
EP2669269B1
(de)
|
2005-05-27 |
2019-05-22 |
The University of North Carolina At Chapel Hill |
Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
|
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
|
ES2691646T3
(es)
|
2005-07-15 |
2018-11-28 |
Micell Technologies, Inc. |
Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
|
|
WO2007011708A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500353A3
(de)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
TWI388344B
(zh)
*
|
2005-08-23 |
2013-03-11 |
Celsion Corp |
儲存奈米微粒調合物之方法
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
US9393215B2
(en)
|
2005-12-02 |
2016-07-19 |
Novartis Ag |
Nanoparticles for use in immunogenic compositions
|
|
EP1985309B1
(de)
|
2005-12-26 |
2016-11-23 |
LTT Bio-Pharma Co., Ltd. |
Nanopartikel enthaltend einen wasserlöslichen nicht-peptidischen niedermolekularen arzneistoff
|
|
US20070166800A1
(en)
*
|
2006-01-13 |
2007-07-19 |
Haixiang Lin |
Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
|
|
WO2007109244A2
(en)
|
2006-03-21 |
2007-09-27 |
Morehouse School Of Medicine |
Novel nanoparticles for delivery of active agents
|
|
CA2996768C
(en)
|
2006-04-26 |
2020-12-08 |
Micell Technologies, Inc. |
Coatings containing multiple drugs
|
|
JP2009544761A
(ja)
|
2006-06-14 |
2009-12-17 |
マクロジェニクス，インコーポレーテッド |
低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
|
|
EP2029173B1
(de)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
|
|
EP2484696B1
(de)
|
2006-08-28 |
2017-08-16 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
|
|
HUE052220T2
(hu)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
|
WO2008032327A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Organic nanoparticles obtained from microemulsions by solvent evaporation
|
|
EP2064335A4
(de)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
|
US8529961B2
(en)
|
2006-10-17 |
2013-09-10 |
Carmell Therapeutics Corporation |
Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
|
|
JP5336382B2
(ja)
|
2006-10-23 |
2013-11-06 |
ミセル テクノロジーズ、インコーポレイテッド |
コーティングの間に基板を荷電するためのホルダー
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
CN101711137B
(zh)
|
2007-01-08 |
2014-10-22 |
米歇尔技术公司 |
具有可生物降解层的支架
|
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
|
US20080175874A1
(en)
*
|
2007-01-19 |
2008-07-24 |
The Procter & Gamble Company |
Applied care compositions comprising functionalized nano-particles
|
|
DE102007005191A1
(de)
|
2007-01-29 |
2008-07-31 |
Rüdiger Marcus Dr. Dr. Flaig |
Verbessertes Ktenat zum Arzneimitteltransport
|
|
DE102007005190A1
(de)
|
2007-01-29 |
2008-07-31 |
Flaig, Rüdiger Marcus, Dr. Dr. |
Selektive Kontaktcytotoxika
|
|
JP4621218B2
(ja)
*
|
2007-02-09 |
2011-01-26 |
有限会社バイオ研 |
Ｔｈ１誘導剤及びその製造方法
|
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
|
ES2918452T3
(es)
|
2007-02-19 |
2022-07-15 |
Marine Polymer Tech Inc |
Composiciones hemostáticas y regímenes terapéuticos
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
US20100303901A1
(en)
*
|
2007-04-26 |
2010-12-02 |
Eyal Shimoni |
Oral delivery of proteins and peptides
|
|
CN101815540B
(zh)
|
2007-05-25 |
2015-08-19 |
米歇尔技术公司 |
用于医疗器材涂层的聚合物膜
|
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
|
EP2158221B1
(de)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
|
WO2009049089A1
(en)
|
2007-10-09 |
2009-04-16 |
Washington University In St. Louis |
Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
|
|
US9446150B2
(en)
|
2007-10-09 |
2016-09-20 |
Washington University |
Particles for imaging
|
|
DE102007054049A1
(de)
|
2007-11-13 |
2009-05-14 |
Flaig, Rüdiger Marcus, Dr. Dr. |
Arzneimitteltransportsystem zur Bekämpfung von Trypanosomen
|
|
KR100961880B1
(ko)
*
|
2007-12-12 |
2010-06-09 |
중앙대학교 산학협력단 |
밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
|
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
|
WO2009105760A2
(en)
*
|
2008-02-22 |
2009-08-27 |
Musculoskeletal Transplant Foundation |
Biologic matrices comprising anti-infective, methods and compositions related thereto
|
|
DK2251006T3
(en)
*
|
2008-02-22 |
2017-10-16 |
Toray Industries |
Microparticles and pharmaceutical compositions thereof
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
CA2721832C
(en)
|
2008-04-17 |
2018-08-07 |
Micell Technologies, Inc. |
Stents having bioabsorbable layers
|
|
WO2009134769A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Novartis Ag |
Nanoparticles for use in pharmaceutical compositions
|
|
EP2282769A4
(de)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
|
KR101005562B1
(ko)
*
|
2008-05-01 |
2011-01-05 |
한국생명공학연구원 |
난용성 약물을 함유하는 균일한 크기의 고분자 나노입자제조방법
|
|
CN102089430B
(zh)
|
2008-05-09 |
2015-02-04 |
Abbvie公司 |
针对渐进性糖化终极产物受体(rage)的抗体及其用途
|
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
EP2297209A4
(de)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
|
EA020753B1
(ru)
|
2008-06-16 |
2015-01-30 |
Бинд Терапьютикс, Инк. |
Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
|
|
AU2009268923B2
(en)
|
2008-06-16 |
2015-09-17 |
Pfizer Inc. |
Drug loaded polymeric nanoparticles and methods of making and using same
|
|
WO2010005726A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences Inc. |
Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
|
|
KR20110040886A
(ko)
|
2008-07-08 |
2011-04-20 |
아보트 러보러터리즈 |
프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
WO2010009335A1
(en)
|
2008-07-17 |
2010-01-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
US20110256059A1
(en)
|
2008-10-28 |
2011-10-20 |
Universidade De Santiago De Compostela |
Nanoparticulate systems prepared from anionic polymers
|
|
WO2010068866A2
(en)
|
2008-12-12 |
2010-06-17 |
Bind Biosciences |
Therapeutic particles suitable for parenteral administration and methods of making and using same
|
|
EA201100765A1
(ru)
|
2008-12-15 |
2012-04-30 |
Бинд Биосаиэнсис |
Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
|
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
|
US8834913B2
(en)
|
2008-12-26 |
2014-09-16 |
Battelle Memorial Institute |
Medical implants and methods of making medical implants
|
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
CN102481195B
(zh)
|
2009-04-01 |
2015-03-25 |
米歇尔技术公司 |
涂覆支架
|
|
EP3366326A1
(de)
|
2009-04-17 |
2018-08-29 |
Micell Technologies, Inc. |
Stents mit gesteuerter elution
|
|
WO2010138193A2
(en)
|
2009-05-27 |
2010-12-02 |
Selecta Biosciences, Inc. |
Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
|
|
EP2437767B1
(de)
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Moleküle mit verlängerter halbwertzeit und verwendungen dafür
|
|
BRPI1015234A2
(en)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
fc regions designed for site specific conjugation.
|
|
EP2453834A4
(de)
|
2009-07-16 |
2014-04-16 |
Micell Technologies Inc |
Medizinische wirkstofffreisetzungsvorrichtung
|
|
WO2011022652A1
(en)
|
2009-08-21 |
2011-02-24 |
Novan, Inc. |
Topical gels
|
|
EP2467173B8
(de)
|
2009-08-21 |
2019-06-19 |
Novan, Inc. |
Wundverbände, verfahren zu ihrer anwendung und verfahren zu ihrer herstellung
|
|
CA2771575A1
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
US20120177741A1
(en)
*
|
2009-09-29 |
2012-07-12 |
Eyegate Pharmaceuticals, Inc. |
Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9237992B2
(en)
|
2009-10-27 |
2016-01-19 |
The Procter & Gamble Company |
Two-step mascara product
|
|
US10034829B2
(en)
|
2010-10-27 |
2018-07-31 |
Noxell Corporation |
Semi-permanent mascara compositions
|
|
US9216145B2
(en)
|
2009-10-27 |
2015-12-22 |
The Procter & Gamble Company |
Semi-permanent cosmetic concealer
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
JP5908406B2
(ja)
|
2009-11-02 |
2016-04-26 |
ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド |
下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
|
|
PH12012501070A1
(en)
|
2009-12-08 |
2017-08-23 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
CN102811743B
(zh)
|
2009-12-11 |
2015-11-25 |
佰恩德治疗股份有限公司 |
冻干治疗颗粒的稳定制剂
|
|
JP5965844B2
(ja)
|
2009-12-15 |
2016-08-10 |
バインド セラピューティックス インコーポレイテッド |
高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
|
|
US9808500B2
(en)
|
2009-12-17 |
2017-11-07 |
Washington University |
Antithrombotic nanoparticle
|
|
US9764043B2
(en)
|
2009-12-17 |
2017-09-19 |
Washington University |
Antithrombotic nanoparticle
|
|
EP2531140B1
(de)
|
2010-02-02 |
2017-11-01 |
Micell Technologies, Inc. |
Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit
|
|
US9028797B2
(en)
|
2010-02-26 |
2015-05-12 |
Nagasaki University |
Composite body for antigen or drug delivery
|
|
WO2011109298A2
(en)
|
2010-03-02 |
2011-09-09 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
US8795762B2
(en)
|
2010-03-26 |
2014-08-05 |
Battelle Memorial Institute |
System and method for enhanced electrostatic deposition and surface coatings
|
|
EP2558072B1
(de)
|
2010-04-15 |
2018-09-26 |
The Washington University |
Prodrug-zusammensetzungen, prodrug-nanopartikel und anwendungsverfahren dafür
|
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
WO2011133655A1
(en)
|
2010-04-22 |
2011-10-27 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
|
US9004791B2
(en)
|
2010-04-30 |
2015-04-14 |
The Procter & Gamble Company |
Package for multiple personal care compositions
|
|
MX2012012927A
(es)
|
2010-05-06 |
2013-05-01 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
|
SG185416A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
|
TWI500427B
(zh)
|
2010-05-14 |
2015-09-21 |
Abbvie Inc |
Ｉｌ－１結合蛋白
|
|
CN107029223A
(zh)
|
2010-05-26 |
2017-08-11 |
西莱克塔生物科技公司 |
合成纳米载体联合疫苗
|
|
US20110318421A1
(en)
*
|
2010-06-24 |
2011-12-29 |
Edward E. Parsonage |
Surface functionalized ceramic nanoparticles
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2012009684A2
(en)
|
2010-07-16 |
2012-01-19 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
ES2665954T3
(es)
|
2010-08-19 |
2018-04-30 |
Zoetis Belgium S.A. |
Anticuerpos anti-NGF y su uso
|
|
ME02637B
(de)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
US9572880B2
(en)
|
2010-08-27 |
2017-02-21 |
Sienna Biopharmaceuticals, Inc. |
Ultrasound delivery of nanoparticles
|
|
JP5945540B2
(ja)
|
2010-08-27 |
2016-07-05 |
シエナ バイオファーマシューティカルズ，インク． |
標的とされた熱変調のための組成物及び方法
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
US8591876B2
(en)
|
2010-12-15 |
2013-11-26 |
Novan, Inc. |
Methods of decreasing sebum production in the skin
|
|
MX2013007332A
(es)
|
2010-12-21 |
2014-01-23 |
Abbvie Inc |
Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
|
|
WO2012088094A2
(en)
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
|
EP2658527B1
(de)
*
|
2010-12-30 |
2022-11-30 |
Micell Technologies, Inc. |
Nanopartikel und oberflächenmodifizierte partikelbeschichtungen, beschichtete ballons und verfahren dafür
|
|
JP6082901B2
(ja)
*
|
2011-01-31 |
2017-02-22 |
オリンパス株式会社 |
ワクチン・アジュバント
|
|
WO2012118819A2
(en)
|
2011-02-28 |
2012-09-07 |
Novan, Inc. |
Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
CN107320734A
(zh)
|
2011-04-29 |
2017-11-07 |
西莱克塔生物科技公司 |
从合成纳米载体中控制释放免疫抑制剂
|
|
US9173824B2
(en)
|
2011-05-17 |
2015-11-03 |
The Procter & Gamble Company |
Mascara and applicator
|
|
US9376495B2
(en)
|
2011-05-21 |
2016-06-28 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use in extending serum half-life
|
|
WO2012166819A1
(en)
|
2011-05-31 |
2012-12-06 |
Micell Technologies, Inc. |
System and process for formation of a time-released, drug-eluting transferable coating
|
|
SG10201505454SA
(en)
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
|
US10117972B2
(en)
|
2011-07-15 |
2018-11-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
JP2014521687A
(ja)
|
2011-07-29 |
2014-08-28 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
AU2012310328A1
(en)
|
2011-09-23 |
2014-04-10 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. |
Anti-Tumor Necrosis Factor-alpha agents and uses thereof
|
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
WO2013059509A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
AR088513A1
(es)
|
2011-10-24 |
2014-06-18 |
Abbvie Inc |
Inmunoenlazantes dirigidos contra esclerostina
|
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
|
EP2788382A2
(de)
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antikörper für epidermalen wachstumsfaktor-rezeptor 3 (her3) gegen domäne ii von her3
|
|
CN104136462B
(zh)
|
2011-12-14 |
2017-06-09 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
|
MX357708B
(es)
|
2011-12-14 |
2018-07-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
|
EP3539982B1
(de)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
US20130195752A1
(en)
|
2012-02-01 |
2013-08-01 |
Regents Of The University Of Minnesota |
Functionalized nanoparticles and methods of use thereof
|
|
WO2013137498A1
(ko)
*
|
2012-03-14 |
2013-09-19 |
인제대학교 산학협력단 |
천연 수용성 고분자로 표면 개질된 생분해성 합성 고분자를 포함하는 조직 재생용 칩의 제조 방법 및 이에 의하여 제조된 조직 재생용 칩
|
|
WO2013163176A1
(en)
|
2012-04-23 |
2013-10-31 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
|
JP2015519954A
(ja)
|
2012-05-15 |
2015-07-16 |
ザ プロクター アンド ギャンブルカンパニー |
睫毛の凝集を定量的に判定する方法
|
|
SG11201407017WA
(en)
|
2012-06-04 |
2014-12-30 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
|
US20140148671A1
(en)
*
|
2012-07-05 |
2014-05-29 |
Empire Technology Development Llc |
Compositions and methods for detecting anastomosis leakage
|
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
|
HUE043998T2
(hu)
|
2012-09-17 |
2019-09-30 |
Pfizer |
Eljárás terápiás nanorészecskék elõállítására
|
|
DK2906286T3
(en)
|
2012-10-11 |
2017-07-17 |
Nanocomposix Inc |
SILVER CHARACTER COMPOSITIONS AND PROCEDURES
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
RU2015115956A
(ru)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン，エルエルシー |
抗ｈ７ｃｒ抗体
|
|
EA201591465A1
(ru)
|
2013-02-08 |
2015-12-30 |
АйАрЭм ЭлЭлСи |
Специфичные участки для модификации антител для получения иммуноконъюгатов
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
CN110269959A
(zh)
|
2013-03-12 |
2019-09-24 |
脉胜医疗技术公司 |
可生物吸收的生物医学植入物
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
|
US9993427B2
(en)
|
2013-03-14 |
2018-06-12 |
Biorest Ltd. |
Liposome formulation and manufacture
|
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
|
WO2014143342A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
CA2907915C
(en)
|
2013-04-03 |
2023-03-07 |
Allertein Therapeutics, Llc |
Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
|
|
CN105307641A
(zh)
|
2013-05-03 |
2016-02-03 |
西莱克塔生物科技公司 |
用于降低不期望体液免疫应答的给药组合
|
|
WO2014186532A1
(en)
|
2013-05-15 |
2014-11-20 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
|
AU2014268298B2
(en)
|
2013-05-24 |
2019-01-17 |
Medlmmune, Llc |
Anti-B7-H5 antibodies and their uses
|
|
EP3003390B1
(de)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54-antikörper und verwendungen davon
|
|
EP3003372B1
(de)
|
2013-06-07 |
2019-10-09 |
Duke University |
Inhibitoren des komplementfaktors h
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
|
HUE034490T2
(en)
|
2013-09-16 |
2018-02-28 |
Astrazeneca Ab |
Therapeutic polymer nanoparticles and methods for their preparation and use
|
|
US20160271230A1
(en)
|
2013-09-17 |
2016-09-22 |
University Health Network (Uhn): Technology Development And Commercialization |
Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
|
|
WO2015058868A1
(en)
|
2013-10-25 |
2015-04-30 |
Pangaea Biotech, S.L. |
Compositions and methods for the treatment of cancer
|
|
CN105814081B
(zh)
|
2013-11-13 |
2021-02-02 |
辉瑞大药厂 |
肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
|
|
TW201536320A
(zh)
|
2013-12-02 |
2015-10-01 |
Abbvie Inc |
治療骨性關節炎之組合物及方法
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
RS60593B1
(sr)
|
2014-01-24 |
2020-08-31 |
Ngm Biopharmaceuticals Inc |
Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
|
|
SG11201606714TA
(en)
|
2014-02-14 |
2016-09-29 |
Andrew S Chi |
Improved methods for the treatment of vascularizing cancers
|
|
EP3450571B1
(de)
|
2014-02-24 |
2023-04-05 |
Celgene Corporation |
Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
|
BR112016020065A2
(pt)
|
2014-03-12 |
2018-02-20 |
Novartis Ag |
sítios específicos para modificar anticorpos para fazer imunoconjugados
|
|
EP3116547B1
(de)
|
2014-03-14 |
2019-06-05 |
Pfizer Inc |
Therapeutische nanopartikel mit einem behandlungsmittel sowie verfahren zur herstellung und verwendung davon
|
|
TWI731535B
(zh)
|
2014-03-21 |
2021-06-21 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
|
JP6832709B2
(ja)
|
2014-05-16 |
2021-02-24 |
メディミューン，エルエルシー |
新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
|
|
WO2015179602A1
(en)
*
|
2014-05-21 |
2015-11-26 |
Albert Einstein College Of Medicine, Inc. |
Compositions and methods for enhancing red blood cell storage time and survivability using nitric oxide releasing hybrid hydrogel nanoparticles
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
US20170291956A1
(en)
|
2014-07-16 |
2017-10-12 |
David Livingston |
HER3 Inhibition in Low-grade Serous Ovarian Cancers
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
|
EA201790551A1
(ru)
|
2014-09-07 |
2017-07-31 |
Селекта Байосайенсиз, Инк. |
Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
UY36401A
(es)
|
2014-11-14 |
2016-06-30 |
Novartis Ag |
Conjugados anticuerpos-fármacos
|
|
KR102693806B1
(ko)
|
2014-12-11 |
2024-08-09 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
MX2017007873A
(es)
|
2014-12-15 |
2017-11-06 |
Univ Johns Hopkins |
Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares.
|
|
WO2016118921A1
(en)
|
2015-01-24 |
2016-07-28 |
Abbvie, Inc. |
Compositions and methods for treating psoriatic arthritis
|
|
CN107250161A
(zh)
|
2015-01-26 |
2017-10-13 |
宏观基因有限公司 |
包含dr5‑结合结构域的多价分子
|
|
PL3265123T3
(pl)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
|
JP6518917B2
(ja)
|
2015-05-29 |
2019-05-29 |
アッヴィ・インコーポレイテッド |
抗ｃｄ４０抗体およびその使用
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
WO2016198351A1
(en)
*
|
2015-06-10 |
2016-12-15 |
Evonik Röhm Gmbh |
Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
US11241394B2
(en)
*
|
2015-06-19 |
2022-02-08 |
The Regents Of The University Of California |
Treating vasculature related diseases or disorders using nanoparticles
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
KR101709628B1
(ko)
*
|
2015-09-10 |
2017-02-24 |
한국과학기술연구원 |
개질된 생분해성 고분자의 제조 방법, 그에 의해 제조된 개질된 생분해성 고분자 및 이를 이용한 생분해성 스텐트
|
|
CA2998183A1
(en)
|
2015-09-11 |
2017-03-16 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating relapsing forms of multiple sclerosis
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
EP3365028B1
(de)
|
2015-10-21 |
2022-08-10 |
The Regents of The University of Michigan |
Nachweis und behandlung von karies und mikrokavitäten mit nanopartikeln
|
|
EP3365369A1
(de)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
|
|
US10441548B2
(en)
|
2015-11-12 |
2019-10-15 |
Graybug Vision, Inc. |
Aggregating microparticles for medical therapy
|
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス， インコーポレイテッド |
グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
|
|
KR102803158B1
(ko)
|
2015-12-02 |
2025-05-08 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
EP3851457A1
(de)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
|
WO2017172437A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Tufts University |
Fabrication of macroporous polymeric hydrogel microparticles
|
|
CN117986363A
(zh)
|
2016-03-31 |
2024-05-07 |
恩格姆生物制药公司 |
结合蛋白及其使用方法
|
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
RS61828B1
(sr)
|
2016-06-08 |
2021-06-30 |
Abbvie Inc |
Anti-b7-h3 antitela i antitelske konjugacije lekova
|
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
|
|
EP3515943A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
|
|
EP3515944A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von immunerkrankungen unter verwendung von pd-1 bindenden proteinen
|
|
WO2018071399A1
(en)
*
|
2016-10-10 |
2018-04-19 |
Abraxis Bioscience, Llc |
Nanoparticle formulations and methods of making and using thereof
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018098370A1
(en)
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
|
US11684583B2
(en)
|
2016-12-08 |
2023-06-27 |
Massachusetts Institute Of Technology |
Compositions and related methods for targeted drug delivery
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP4599848A3
(de)
|
2017-03-11 |
2025-12-03 |
Cartesian Therapeutics, Inc. |
Verfahren und zusammensetzungen in zusammenhang mit einer kombinierten behandlung mit entzündungshemmenden mitteln und synthetischen nanoträgern mit einem immunsuppressivum
|
|
MX2019011242A
(es)
|
2017-03-23 |
2020-01-21 |
Graybug Vision Inc |
Farmacos y composiciones para el tratamiento de trastornos oculares.
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
MX2019013363A
(es)
|
2017-05-10 |
2020-01-13 |
Graybug Vision Inc |
Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
|
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
|
CN111148762A
(zh)
|
2017-05-31 |
2020-05-12 |
斯特库伯株式会社 |
免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
|
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー．， インコーポレイテッド |
Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
|
JP6865491B2
(ja)
*
|
2017-07-25 |
2021-04-28 |
レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． |
血管内生理活性物質送達用組成物
|
|
CN111615520A
(zh)
|
2017-12-01 |
2020-09-01 |
辉瑞大药厂 |
抗cxcr5抗体及其组合物和用途
|
|
CN111417651B
(zh)
|
2017-12-01 |
2023-09-29 |
诺华股份有限公司 |
多瘤病毒中和抗体
|
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
|
KR102088663B1
(ko)
*
|
2018-03-20 |
2020-03-13 |
한국세라믹기술원 |
친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
|
|
WO2019190984A1
(en)
|
2018-03-29 |
2019-10-03 |
Pfizer Inc. |
Lfa3 variants and compositions and uses thereof
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
EP3784705A4
(de)
*
|
2018-04-23 |
2022-03-02 |
Graybug Vision, Inc. |
Verbesserte kontinuierliche mikropartikelherstellung
|
|
CN119490583A
(zh)
|
2018-05-31 |
2025-02-21 |
诺华股份有限公司 |
乙型肝炎抗体
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
CA3102036A1
(en)
|
2018-06-18 |
2019-12-26 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
|
KR20250024129A
(ko)
|
2018-07-20 |
2025-02-18 |
피에르 파브르 메디카먼트 |
Vista의 수용체
|
|
CN112823167B
(zh)
|
2018-09-07 |
2025-07-15 |
辉瑞大药厂 |
抗-αvβ8抗体和组合物及其用途
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
SG11202102851XA
(en)
|
2018-09-27 |
2021-04-29 |
Celgene Corp |
SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
|
|
JP2022513317A
(ja)
|
2018-09-28 |
2022-02-07 |
ヨッヘン ライザー |
ｓｕＰＡＲならびに急性腎傷害の予測および治療
|
|
KR20210099614A
(ko)
|
2018-12-04 |
2021-08-12 |
노파르티스 아게 |
Cd3에 대한 결합 분자 및 이의 용도
|
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗ＴＮＦ－α抗體
|
|
AU2019409132B2
(en)
|
2018-12-21 |
2026-08-06 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
WO2020158833A1
(ja)
|
2019-01-31 |
2020-08-06 |
セルメディシン株式会社 |
無機塩類タンパク複合医療機器
|
|
AU2020234394B2
(en)
|
2019-03-08 |
2024-02-15 |
AbTis Co., Ltd. |
Site-specific antibody conjugation and antibody-drug conjugate as specific example thereof
|
|
WO2020205827A1
(en)
|
2019-04-01 |
2020-10-08 |
Rush University Medical Center |
Reagents and assays using modified integrin domains
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
JP7137696B2
(ja)
|
2019-05-14 |
2022-09-14 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を予防するための方法および組成物
|
|
US12553041B2
(en)
|
2019-06-04 |
2026-02-17 |
Cartesian Therapeutics Inc. |
Formulations and doses of pegylated uricase
|
|
EP4004214A1
(de)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Gentechnisch hergestelltes nukleinsäureregulationselement und verwendungsverfahren dafür
|
|
KR20220088428A
(ko)
|
2019-09-26 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
|
|
KR20220088438A
(ko)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
|
|
JP7600528B2
(ja)
*
|
2020-03-16 |
2024-12-17 |
株式会社リコー |
粒子の製造方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021220218A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Immunoglobulin variants
|
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
|
ES3075793T3
(en)
|
2020-05-13 |
2026-08-07 |
Disc Medicine Inc |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
AU2021273014A1
(en)
|
2020-05-13 |
2022-11-17 |
AbbVie Deutschland GmbH & Co. KG |
Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
|
|
WO2021257679A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Ｃｄ２０結合分子及びその使用
|
|
CA3186065A1
(en)
|
2020-07-16 |
2022-01-20 |
Xiaohu FAN |
Cd19 binding molecules and uses thereof
|
|
TW202212354A
(zh)
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
IL300505A
(en)
|
2020-08-10 |
2023-04-01 |
Janssen Biotech Inc |
Materials and methods for the production of biologically engineered virus-specific lymphocytes
|
|
CN114073791B
(zh)
*
|
2020-08-21 |
2022-05-31 |
中国科学院化学研究所 |
一种软骨组织工程支架及其制备方法与应用
|
|
WO2022072597A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Diomics Corporation |
Transdermal medicament delivery device
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
EP4225777A2
(de)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Adeno-assoziierte viren zur okularen verabreichung einer gentherapie
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20250199010A1
(en)
|
2020-12-31 |
2025-06-19 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
JP2024507958A
(ja)
|
2021-02-26 |
2024-02-21 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
|
|
WO2022208322A1
(en)
|
2021-03-29 |
2022-10-06 |
Tomson Technologies Llc |
Extended release asphaltene inhibitor composition
|
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
EP4413019A2
(de)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Rekombinante adeno-assoziierte viren zur zns-tropen verabreichung
|
|
EP4413018A1
(de)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Rekombinante adeno-assoziierte viren zur gezielten abgabe
|
|
US20250011428A1
(en)
|
2021-10-28 |
2025-01-09 |
Novartis Ag |
Engineered fc variants
|
|
EP4423285A1
(de)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Manipulierte regulatorische nukleinsäureelemente sowie verfahren und verwendungen davon
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
AU2023217968A1
(en)
|
2022-02-09 |
2024-09-26 |
Janssen Biotech, Inc. |
Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
|
|
EP4493226A1
(de)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modifizierte muskelspezifische promotoren
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
IL316174A
(en)
|
2022-04-26 |
2024-12-01 |
Novartis Ag |
Multiple specific antibodies targeting IL-13 and IL-18
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
CN115006605A
(zh)
*
|
2022-07-20 |
2022-09-06 |
苏州中天医疗器械科技有限公司 |
一种药物涂层球囊及其制备方法和应用
|
|
CN119907674A
(zh)
|
2022-07-22 |
2025-04-29 |
詹森生物科技公司 |
遗传指令向效应免疫细胞的增强转移
|
|
CN120077064A
(zh)
|
2022-08-05 |
2025-05-30 |
詹森生物科技公司 |
用于治疗脑肿瘤的转铁蛋白受体结合蛋白
|
|
EP4565331A1
(de)
|
2022-08-05 |
2025-06-11 |
Janssen Biotech, Inc. |
Cd98-bindende konstrukte zur behandlung von hirntumoren
|
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
EP4594442A1
(de)
*
|
2022-09-28 |
2025-08-06 |
ChampionX LLC |
Asphalteninhibitorzusammensetzung mit verlängerter freisetzung
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
CN116211732B
(zh)
*
|
2023-01-03 |
2023-11-17 |
广州澳特朗生物技术有限公司 |
一种具有组织修护、抗皱和舒缓功效的纤连蛋白纳米制剂及其制备方法和应用
|
|
TW202448505A
(zh)
|
2023-03-01 |
2024-12-16 |
美商普泛森生技公司 |
用於治療第1型糖尿病的方法及組成物
|
|
TW202506177A
(zh)
|
2023-03-30 |
2025-02-16 |
美商普泛森生技公司 |
減少外源性胰島素使用之方法
|
|
EP4694904A2
(de)
|
2023-04-13 |
2026-02-18 |
REGENXBIO Inc. |
Targeting von aav-kapsiden, verfahren zur herstellung und verwendung davon
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
EP4750808A1
(de)
|
2023-07-27 |
2026-06-03 |
Provention Bio, Inc. |
Verfahren zur behandlung von typ-1-diabetes
|
|
CN116874996B
(zh)
*
|
2023-09-01 |
2023-12-05 |
山东龙兴塑膜科技股份有限公司 |
一种改性聚酯的制备方法及在覆膜铁用聚酯薄膜中的应用
|
|
AU2024386366A1
(en)
|
2023-11-23 |
2026-06-04 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025262564A1
(en)
|
2024-06-17 |
2025-12-26 |
Pfizer Inc. |
Use of anti-cxcr5 antibodies
|
|
US20260167709A1
(en)
|
2024-09-11 |
2026-06-18 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026086785A1
(en)
|
2024-10-21 |
2026-04-30 |
Shenzhen Wondercel Biotechnology Limited |
Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c
|
|
US20260217815A1
(en)
|
2025-01-29 |
2026-07-30 |
Novartis Ag |
Treatment of atopic dermatitis with multispecific antibodies
|
|
CN120681889B
(zh)
*
|
2025-06-24 |
2025-12-12 |
广东工业大学 |
一种利用微生物菌剂快速降解湖泊水体难降解溶解性有机物的方法
|